Sanofi Pasteur Gains FDA Approval for DENGVAXIA Following Multi-Year Post-Approval Safety Review

Sanofi Pasteur's DENGVAXIA carries one of the more instructive post-approval regulatory records in the biologics space, with four FDA approval letters spanning May 2019 through June 2023 documenting a label that has evolved substantially since initial licensure under STN 125682. For biologics manufacturers managing complex vaccines with serostatus-dependent safety profiles, the product's regulatory trajectory offers a direct read on how post-market commitments and label revisions interact under 21 CFR Part 601.

The current approved indication is tightly scoped: prevention of dengue disease caused by serotypes 1, 2, 3, and 4 in individuals aged 6 through 16 years with laboratory-confirmed previous dengue infection living in endemic areas. That serostatus prerequisite is not incidental. It reflects post-approval safety findings that reshaped the product's risk-benefit calculus for seronegative recipients, a constraint now embedded in labeling and supported by demographic subgroup analyses referenced in the June 30, 2023 Clinical Review Memo.

The supporting document package released by FDA is dense: two June 2023 review memos (clinical and statistical), four approval letters across a four-year window, and the original May 2019 Summary Basis for Regulatory Action alongside its accompanying statistical review. QA directors and regulatory affairs leads at biologics manufacturers should treat this document set as a working reference for how FDA structures iterative label negotiations when post-market data surfaces population-specific risk signals.

For teams currently managing post-approval commitments on live attenuated or combination biologics, DENGVAXIA's approval history illustrates the operational weight of serostatus-based prescribing restrictions. Implementing such restrictions requires coordination across labeling, pharmacovigilance, and risk communication systems, each of which must remain audit-ready under 21 CFR Part 211 and aligned with ICH Q10 quality system expectations for lifecycle management.

The June 30, 2023 approval letter represents the most recent regulatory action on file, and the completeness of FDA's published document trail makes DENGVAXIA a reference-class case for biologics teams preparing responses to post-market safety signals or negotiating label updates with the agency.

Source: FDA Vaccines, Blood and Biologics product page via What's New Vaccines Blood Biologics RSS Feed, July 6, 2026.